US Patent

US9018210 — Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation

Composition of Matter · Assigned to Cytokinetics Inc · Expires 2033-11-25 · 8y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects substituted benzaldehyde compounds that act as allosteric modulators of hemoglobin, including the active substance Oxbryta.

USPTO Abstract

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Drugs covered by this patent

Patent Metadata

Patent number
US9018210
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-11-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Cytokinetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.